iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 Novo said its research shows US Medicare recipients are twice as likely to prefer a weight-loss pill to a shot, a preference it hopes will help it win market share from rival GLP-1 Antagonists Increase Plan Drug
Description
However, it is not a direct treatment for fatigue
The remaining ~75% comes from fat mass
This tracks
Some patients use microdosing after completing a standard GLP-1 plan, while others may be eligible based on their medical history, goals, and provider recommendation
